🇺🇸 FDA
Pipeline program

Aprepitant injectable emulsion

HTX-019-202

Phase 2 small_molecule terminated

Quick answer

Aprepitant injectable emulsion for COVID-19 is a Phase 2 program (small_molecule) at HERON THERAPEUTICS, INC. /DE/ with 1 ClinicalTrials.gov record(s).

Program details

Company
HERON THERAPEUTICS, INC. /DE/
Indication
COVID-19
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials